Specialties

During pregnancy, insulin resistance increases and caffeine metabolism decreases, affecting maternal cardiometabolic health.

Is current evidence supportive of metformin as an adjunct therapy for pregnant women with diabetes?

The interaction between systolic blood pressure (SBP) and the effects of empagliflozin in patients with heart failure with reduced ejection fraction (HFrEF).

SGLT2 inhibitors are not created equal; patient-specific characteristics need to be considered for best efficacy.

Is weight loss always as beneficial as we think?

Is there an ideal approach to screen and diagnose children and adolescents for prediabetes and diabetes?

Study shows that breastfeeding can provide diabetes inhibiting effects for over three years.

This review examines the differing arguments recent studies have made regarding blood pressure goals and cardiovascular risk. 

CREDENCE trial shows that canagliflozin, an SGLT2 inhibitor, lowers the risk of cardiovascular and renal events in patients with T2DM, regardless of prior history of heart failure. 

Sexual health questionnaires can be used as an early detection tool for men's CVD, coronary heart disease, stroke, and T2D.